GlassScriptPhysician profile
Robert G Leikin
NPI 1316051808
$4,303.59
in general payments reported to CMS, 2019-2025
23 companies · $722 in 2025
The $722 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $218 · 2021: $281 · 2022: $312 · 2023: $555 · 2024: $713 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,226.23 | 2019-2020 | |
| Alcon Vision LLC | $980.55 | 2019-2025 | Clareon, Precision7, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $289.42 | 2019-2021 | |
| Abbvie INC. | $260.07 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $173.02 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Vision Care, INC. | $160.72 | 2019-2023 | Acuvue |
| Rxsight INC | $159.47 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sight Sciences, INC. | $158.12 | 2023-2024 | Omni Surgical System, Sion Surgical Instrument |
| Novartis Pharmaceuticals Corporation | $151.43 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $149.35 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $118.49 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $82.82 | 2023-2024 | Omidria, Rayone Emv, Rayone Spheric |
| Oyster Point Pharma, INC. | $65.20 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $60.81 | 2024-2025 | Oxervate |
| Coopervision INC. | $58.88 | 2019-2025 | Myday Contact Lens |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $51.40 | 2019 | |
| Thea Pharma INC. | $38.69 | 2023 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $38.10 | 2021 | |
| Genentech USA, INC. | $22.12 | 2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $21.89 | 2025 | Eylea Hd |
| Allergan, INC. | $13.89 | 2022 | |
| Shire North American Group INC | $11.97 | 2019 | |
| Eyevance Pharmaceuticals LLC | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leikin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.